Becton Dickinson and Co (BDX) : L S Advisors Inc added new position in Becton Dickinson and Co during the most recent quarter end. The investment management firm now holds 42,977 shares of Becton Dickinson and Co which is valued at $7,477,138 , the company said in a statement filed on Aug 15, 2016 with the SEC.Becton Dickinson and Co makes up approximately 1.65% of L S Advisors Inc’s portfolio.
Other Hedge Funds, Including , Two Sigma Advisers Lp boosted its stake in BDX in the latest quarter, The investment management firm added 27,436 additional shares and now holds a total of 36,819 shares of Becton Dickinson and Co which is valued at $6,405,770. Becton Dickinson and Co makes up approx 0.03% of Two Sigma Advisers Lp’s portfolio.Nicholas Co Inc Wi reduced its stake in BDX by selling 2,400 shares or 88.89% in the most recent quarter. The Hedge Fund company now holds 300 shares of BDX which is valued at $52,194.Welch Forbes reduced its stake in BDX by selling 104 shares or 0.13% in the most recent quarter. The Hedge Fund company now holds 78,390 shares of BDX which is valued at $13,779,394. Becton Dickinson and Co makes up approx 0.41% of Welch Forbes’s portfolio.Strs Ohio boosted its stake in BDX in the latest quarter, The investment management firm added 1,379 additional shares and now holds a total of 134,290 shares of Becton Dickinson and Co which is valued at $23,437,634. Becton Dickinson and Co makes up approx 0.10% of Strs Ohio’s portfolio.
Becton Dickinson and Co closed down -0.19 points or -0.11% at $177.02 with 6,09,017 shares getting traded on Thursday. Post opening the session at $177.71, the shares hit an intraday low of $175.71 and an intraday high of $177.78 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Becton Dickinson and Co reported $2.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.15 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.20. The company had revenue of $3198.00 million for the quarter, compared to analysts expectations of $3202.11 million. The company’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS.
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.